Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 15/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 14/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.45 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.43 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688614 | 0.80 | PDGFRB (0.42) | PDGFRBKITKDRMEN1ALDH1A1 | |
| SCHEMBL688901 | 0.79 | PDGFRB (0.55) | PDGFRBKITKDRKDM4EALDH1A1 | |
| SCHEMBL688926 | 0.75 | PDGFRB (0.41) | PDGFRBKITKDRALDH1A1KMT2A | |
| SCHEMBL689067 | 0.71 | BRD4 (0.45) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL689002 | 0.68 | PDGFRB (0.58) | PDGFRBKITKDRL3MBTL1KDM4E | |
| SCHEMBL1085278 | 0.67 | L3MBTL3 (0.65) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL5628863 | 0.66 | PDGFRB (0.56) | PDGFRBKITKDRMEN1KMT2A | |
| SCHEMBL688491 | 0.65 | BRD4 (0.58) | L3MBTL1KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL688015 | 0.64 | PDGFRB (0.59) | PDGFRBKITKDRL3MBTL1KDM4E | |
| SCHEMBL687464 | 0.64 | PDGFRB (0.40) | PDGFRBKITKDRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084621-B2 | 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof | Jiangsu Simcere Pharmaceutical R&D Co. Ltd. (CN) | 2011-12-27 | — | — | US | disclosed |
| US-20100160318-A1 | 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof | JIANGSU SIMCERE PHARMACEUTICAL R&D CO., LTD. (CN) | 2010-06-24 | — | — | US | disclosed |
| EP-2123649-A1 | 3-PYRROLO-CYCLOHEXYLENE-2-DIHYDRO-INDOLINONE DERIVATIVES AND USES THEREOF | Jiangsu Simcere Pharmaceutical R&D Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160318-A1 | 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof | PTK2B, DMPK, STK25 | PDGFRB 504/4885KIT 324/4885KDR 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.